Literature DB >> 2009529

Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo.

T W Chin1, R L Parry, P K Donahoe.   

Abstract

Müllerian inhibiting substance (MIS) causes regression of the müllerian duct in the male fetus. Bovine MIS has been reported to inhibit the growth of some gynecological tumors. Recombinant human MIS (rhMIS) produced in transfected Chinese hamster ovary cells has been highly purified by immunoaffinity chromatography. The introduction of a salt wash prior to elution of MIS from the affinity column removes a growth-stimulating factor(s) derived from Chinese hamster ovary cells. This immunopurified rhMIS caused significant inhibition (34-59% survival) of A431 (a vulvar epidermoid carcinoma), HT-3 (a cervical carcinoma), HEC-1-A (an endometrial adenocarcinoma), NIH:OVCAR-3 (an ovarian adenocarcinoma), and OM431 (an ocular melanoma) human cell lines in colony inhibition assays. Two cell lines, Hep 3B (a hepatocellular carcinoma) and RT4 (a bladder transitional cell papilloma), were unresponsive to immunopurified rhMIS. Using an in vivo subrenal capsule assay in irradiated CD-1 mice, the growth of A431 and OM431 cells was inhibited by immunopurified rhMIS. We conclude that rhMIS inhibits the growth of certain tumor cell lines in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2009529

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer.

Authors:  E Basal; T Ayeni; Q Zhang; C Langstraat; P K Donahoe; D Pepin; X Yin; E Leof; W Cliby
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

2.  CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies.

Authors:  Alba Rodriguez-Garcia; Prannda Sharma; Mathilde Poussin; Alina C Boesteanu; Nicholas G Minutolo; Sarah B Gitto; Dalia K Omran; Matthew K Robinson; Gregory P Adams; Fiona Simpkins; Daniel J Powell
Journal:  Mol Ther       Date:  2019-12-06       Impact factor: 11.454

3.  Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo.

Authors:  A E Stephen; P T Masiakos; D L Segev; J P Vacanti; P K Donahoe; D T MacLaughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

4.  Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.

Authors:  Henry L Chang; Rafael Pieretti-Vanmarcke; Fotini Nicolaou; Xianlin Li; Xiaolong Wei; David T MacLaughlin; Patricia K Donahoe
Journal:  Gynecol Oncol       Date:  2010-11-06       Impact factor: 5.482

5.  Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cells.

Authors:  Seong Jin Hwang; Min Jung Suh; Joo Hee Yoon; Mee Ran Kim; Ki Sung Ryu; Suk Woo Nam; Patricia K Donahoe; David T Maclaughlin; Jang Heub Kim
Journal:  Int J Oncol       Date:  2011-05-13       Impact factor: 5.650

6.  Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancer.

Authors:  Jae Yen Song; Hyun Hee Jo; Mee Ran Kim; Young Oak Lew; Ki Sung Ryu; Jung Ho Cha; Chang Suk Kang; Patricia K Donahoe; David T MacLaughlin; Jang Heub Kim
Journal:  Int J Oncol       Date:  2012-02-14       Impact factor: 5.650

7.  Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts.

Authors:  Seungyoun Jung; Naomi Allen; Alan A Arslan; Laura Baglietto; Aurelio Barricarte; Louise A Brinton; Brian L Egleston; Roni T Falk; Renée T Fortner; Kathy J Helzlsouer; Yutang Gao; Annika Idahl; Rudolph Kaaks; Vittorio Krogh; Melissa A Merritt; Eva Lundin; N Charlotte Onland-Moret; Sabina Rinaldi; Helena Schock; Xiao-Ou Shu; Patrick M Sluss; Paul N Staats; Carlotta Sacerdote; Ruth C Travis; Anne Tjønneland; Antonia Trichopoulou; Shelley S Tworoger; Kala Visvanathan; Elisabete Weiderpass; Anne Zeleniuch-Jacquotte; Joanne F Dorgan
Journal:  Int J Cancer       Date:  2017-10-04       Impact factor: 7.396

Review 8.  Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

Review 9.  HEC-1 cells.

Authors:  Hiroyuki Kurarmoto; Mieko Hamano; Manami Imai
Journal:  Hum Cell       Date:  2002-06       Impact factor: 4.174

10.  The Müllerian inhibiting substance type 2 receptor suppresses tumorigenesis in testes with sustained β-catenin signaling.

Authors:  Pradeep S Tanwar; Arno E Commandeur; LiHua Zhang; Makoto M Taketo; Jose M Teixeira
Journal:  Carcinogenesis       Date:  2012-09-07       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.